According to a new report by Polaris Market Research, the global psychiatric digital biomarkers market was valued at USD 630.40 million in 2024 and is projected to reach USD 5,543.77 million by 2034, expanding at a CAGR of 24.3% over the forecast period. Growth is underpinned by rising integration of artificial intelligence and machine learning, expanding telehealth adoption, and accelerating use of digital biomarkers by pharmaceutical companies across key end-use industries.

What Is Driving Psychiatric Digital Biomarkers Market Growth?

Demand is climbing as the rising global prevalence of mental health conditions such as depression, anxiety, and schizophrenia converges with rapid advancements in wearable and mobile health technology. Manufacturers and clinicians are prioritizing objective, data-driven diagnostic tools, pushing psychiatric digital biomarker adoption across the healthcare and life sciences industries. Polaris analysts note that nearly 60 million US adults experienced a mental illness between 2021 and 2022, positioning the wearable segment for sustained double-digit growth through 2034, with healthcare companies emerging as the largest revenue contributor and mobile-based applications posting notable incremental gains.

Key Trends Shaping the Psychiatric Digital Biomarkers Industry

AI-Enabled Diagnostic Innovation

Artificial intelligence is increasingly used to analyze digital footprints, voice patterns, and app usage to flag early signs of psychiatric disorders, while machine learning uncovers hidden correlations between multimodal data and specific conditions, supporting continued technology advancement across the industry.

Regulatory Momentum From FDA and EMA

Growing regulatory focus on digital health tools, including initiatives from the FDA and the European Medicines Agency, is encouraging innovation and accelerating approvals for digital biomarkers in psychiatric applications, strengthening the regulatory landscape supporting market adoption.

Wearable and Telehealth Convergence

The widespread adoption of smartwatches, biosensors, and mobile applications with mental health tracking functionality is driving demand for continuous, real-time psychiatric assessment, reinforcing a positive market outlook as telehealth platforms increasingly integrate biomarker data streams.

Market Segmentation: Breaking Down the Psychiatric Digital Biomarkers Market

Polaris segments the psychiatric digital biomarkers market by type, clinical practice, end use, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Type

The wearable segment led the market in 2024, accounting for the largest share of revenue on the strength of growing integration of advanced biosensors in smartwatches, fitness trackers, and wearable EEG devices. Mobile-based applications are also expanding quickly as remote psychiatric assessment combined with AI-driven analytics accelerates adoption among clinicians and researchers.

By End Use

Healthcare companies remain the dominant end-use segment, driven by pharmaceutical and MedTech firms investing in AI-powered biomarker analytics to support drug development and clinical trials. Healthcare providers are gaining share as digital biomarkers are integrated into telepsychiatry services, signaling where near-term demand for "psychiatric digital biomarkers market" solutions is shifting.

Read More @ https://www.polarismarketresearch.com/industry-analysis/psychiatric-digital-biomarkers-market

By Clinical Practice

Among clinical practice categories, monitoring and diagnostic applications captured significant share in 2024, while predictive and prognostic use cases are expected to post the strongest incremental growth as AI-driven analytics mature and clinical validation expands.

Regional Outlook: Where Is Psychiatric Digital Biomarkers Growing Fastest?

North America led the market in 2024 on the back of advanced healthcare infrastructure, strong investment in digital health technologies, and favorable regulatory policies, while Europe is expected to post the fastest CAGR through 2034, driven by government-backed digital health transformation initiatives such as the EU4Health program. Within North America, the United States remains the largest single market; within Europe, growing collaboration between research institutions, MedTech firms, and healthcare providers is the primary growth engine. Asia Pacific rounds out the top three, supported by rising mental health awareness and expanding digital health infrastructure.

Competitive Landscape: Leading Psychiatric Digital Biomarkers Companies

Key players profiled in the report include Biogen, Empatica Inc., Brainomix, Clario, Huma, IXICO plc, Koneksa Health, PureTech Health PLC, Sonde Health, Inc., and VivoSense, who are focusing on advancing machine learning algorithms, wearable biosensors, and mobile-based psychiatric assessments to strengthen market position across the wearable and healthcare-company segments outlined above. Recent moves include Indivi's March 2024 partnership with Biogen to advance digital biomarkers for Parkinson's disease, and Quanterix's July 2023 launch of the LucentAD biomarker blood test to support Alzheimer's diagnosis, both aimed at deepening clinical and commercial share.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the psychiatric digital biomarkers market forecast, this report benchmarks market share, segment-level pricing, and forecast data — by type, clinical practice, end use, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking mobile-based applications as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Japan Fitness App Market

Precision Chemicals Market

Power SCADA Market

Radiodermatitis Market

Cervical Dysplasia Market

Hand Sanitizer Market

Oncology Clinical Trials Market

Photovoltaics Market

EMI Shielding Market